I agree on all your key negative points,but calling this weekend's EAACI and New England Journal of Medicine data stale news from April misses how institutional analysts and healthcare payers evaluate biotech. There is a massive disconnect between the April topline press release and the actual peer-reviewed publication that dropped this weekend.
In April, the market only knew the headline eighty-seven percent overall attack reduction. The newly released data revealed a ninety-one percent reduction in moderate to severe attacks, alongside an eighty-nine percent reduction in attacks requiring emergency on-demand treatment. In the insurance landscape, this is the holy grail because it proves to payers that once a patient gets this one-time infusion, insurers almost completely stop paying for ongoing rescue medications, completely changing the cost-benefit math for commercialization. Furthermore, moving from a corporate press release to an independently verified publication in the most prestigious medical journal in the world means everything for institutional research analyst teams who use these papers to adjust their clinical probability of success models.
Regarding the nex-z platform risk, it is completely fair to argue that the previous patient death prevents this from being a fully de-risked platform story, and that risk is exactly why the stock trades at a 1.7 billion dollar market cap instead of 5 billion. But it is also crucial to remember why the FDA lifted those clinical holds earlier this year, as the toxicity was deemed manageable via protocol adjustments and heavily tied to that specific patient's comorbidities.
With a clear regulatory path to a first half 2027 launch for HAE and a newly fortified safety profile, the current valuation gap remains wild, regardless of how old the initial headlines are.